This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cellceutix Poster Presentation On Its P53 Cancer Breakthrough Attracts Wide Interest At 102nd AACR Meeting

BEVERLY, Mass., April 11, 2011 /PRNewswire/ -- Cellceutix Corporation (OTCQB: CTIX), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat severe medical conditions including drug-resistant cancers, is pleased to announce that their recent poster at the 102nd Annual Meeting of the American Association for Cancer Research (AACR)  generated significant interest from major Pharmaceutical companies and numerous investigators.  The poster, entitled, "Kevetrin™, A Novel Small Molecule, Activates p53, Enhances Expression of p21, Induces Cell Cycle Arrest and Apoptosis in a Human Cancer Cell Line" was showcased by Cellceutix at the AACR Meeting held April 2-6, 2011 in Orlando, FL. The poster is available for viewing on

Cellceutix was represented by its Chief Scientific Officer, Dr. Krishna Menon, and two of its scientific consultants, Dr. Ashok Kumar and Dr. Sylvia A. Holden.  Dr. Holden received her PhD from Boston University followed by an NIH-funded post-doctoral fellowship at Dana-Farber Cancer Institute in the Division of Cancer Pharmacology headed by chemotherapy pioneer and Cellceutix Scientific Advisor, Dr. Emil Frei III.  Before joining Cellceutix, Dr. Holden was the Director of Pharmacology at EMD Serono in Billerica, MA (Merck KGaA) and Director of Tumor Biology at Shionogi BioResearch Corp., in Lexington, MA (presently Synta Pharmaceuticals).  She was awarded 5 US patents and has published over 100 publications in peer-reviewed journals, including 12 first-authored papers and publications in Science and Nature Medicine.

Commenting on the poster session, Dr. Holden stated, "I have been participating in the AACR annual meeting for more than twenty years and I can't recall a poster session ever being as active as Cellceutix's was this year.  There were people waiting at our poster before we had arrived and a steady flow of elite scientists at all times up to and through the closing of the session."  Dr. Holden continued, "The manner in which people gravitated to Cellceutix to learn about Kevetrin and its p53 breakthroughs attests to the value of Kevetrin as a novel cancer therapy.  We were approached for in-depth conversations by representatives of the world's largest pharmaceutical companies and most prestigious universities in the United States.  Moreover, we held a meeting with the National Cancer Institute to discuss the future for Kevetrin development as well.  Now that people have gotten a first-hand look at our research explaining the mechanism of action for Kevetrin, the interest that was starting to brew is truly intensifying as organizations of all sizes want to continue discussions back at our offices and lab."

Additionally, the Cellceutix team was proud that once again during this year's convention, Cellceutix Scientific Advisor, Dr. Emil Frei III, was honored by the AACR.  Dr. Frei was a previous recipient of accolades from the AACR as the inaugural AACR Award for Lifetime Achievement in Cancer Research was given to him in 2004.  In 2009, the AACR recognized Cellceutix cancer drug Kevetrin, as an elite drug in development due to promising potency during its first "Frontiers in Basic Cancer Research Meeting."

About Cellceutix

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs